Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;105(1):16-23.
doi: 10.1111/ejh.13410. Epub 2020 Apr 15.

The changing epidemiology of the ageing thalassaemia populations: A position statement of the Thalassaemia International Federation

Dimitrios Farmakis  1   2 , Anastasios Giakoumis  3 , Michael Angastiniotis  2 , Androulla Eleftheriou  2
Affiliations
Review

The changing epidemiology of the ageing thalassaemia populations: A position statement of the Thalassaemia International Federation

Dimitrios Farmakis et al. Eur J Haematol. 2020 Jul.

Abstract

Therapeutic advances in β-thalassaemia have gradually lead to a significant improvement in prognosis over the past few decades. As a result, patients living in areas where disease-specific programmes offering access to modern therapy are in place experience a new era of prolonged survival that tends to reach that of the normal population. This ageing thalassaemia population, however, faces a new spectrum of comorbidities resulting from increasing age that may jeopardise the advances in prognosis provided by current therapy and thus poses new challenges in diagnosis, monitoring and treatment. In this position paper of the Thalassaemia International Federation, we review the changing epidemiology and clinical spectrum of patients with β-thalassaemia and propose actions to be undertaken in order to address the emerging spectrum of comorbidities resulting from ageing.

Keywords: Thalassaemia; ageing; comorbidities; survival.

PubMed Disclaimer

References

REFERENCES

    1. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193.
    1. Weidlich D, Kefalas P, Guest JF. Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom. Transfusion. 2016;56(5):1038-1045.
    1. Voskaridou E, Kattamis A, Fragodimitri C, et al. Papassotiriou I; Greek Haemoglobinopathies Study Group. National registry of hemoglobinopathies in Greece: updated demographics, current trends in affected births, and causes of mortality. Ann Hematol. 2019;98(1):55-66.
    1. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation. 1964;30:698-705.
    1. Ladis V, Chouliaras G, Berdoukas V, et al. Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population. Eur J Haematol. 2011;86(4):332-338.